Last reviewed · How we verify
Lucemyra (LOFEXIDINE)
Lucemyra works by activating the alpha-2A adrenergic receptor to reduce the release of norepinephrine, a neurotransmitter involved in withdrawal symptoms.
Lucemyra (lofexidine) is a small molecule drug that targets the alpha-2A adrenergic receptor to treat opioid withdrawal. It was originally developed by US WorldMeds LLC and is now owned by Biocorrx Pharmaceuticals. Lucemyra was FDA-approved in 2018 for the management of opioid withdrawal symptoms. The drug has a half-life of 12 hours and high bioavailability of 90%. It is now off-patent with multiple generic manufacturers.
At a glance
| Generic name | LOFEXIDINE |
|---|---|
| Sponsor | Biocorrx Pharms |
| Drug class | lofexidine |
| Target | Alpha-2A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2018 |
Mechanism of action
Lofexidine is central alpha-2 adrenergic agonist that binds to receptors on adrenergic neurons. This reduces the release of norepinephrine and decreases sympathetic tone.
Approved indications
- Opioid withdrawal
Common side effects
- Orthostatic hypotension
- Bradycardia
- Dizziness
- Somnolence
- Sedation
- Dry mouth
- Insomnia
- Diarrhea
- Anxiety
- Chills
- Hyperhidrosis
- Extremity pain
Key clinical trials
- Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal (PHASE2)
- An Innovative Intervention for OUD Treatment (PHASE2,PHASE3)
- Sublingual Dexmedetomidine for Treating Opioid Withdrawal (PHASE1,PHASE2)
- Evaluating Buspirone to Treat Opioid Withdrawal (PHASE2)
- Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids (PHASE2)
- Assessing a Clinically-meaningful Opioid Withdrawal Phenotype (PHASE2)
- A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects (PHASE1)
- Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lucemyra CI brief — competitive landscape report
- Lucemyra updates RSS · CI watch RSS
- Biocorrx Pharms portfolio CI